

Vinayak Muralidhar

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8091600/publications.pdf>

Version: 2024-02-01

100
papers

2,034
citations

361413

20
h-index

265206

42
g-index

100
all docs

100
docs citations

100
times ranked

4100
citing authors

#	ARTICLE	IF	CITATIONS
1	Identifying the Best Candidates for Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography as the Primary Staging Approach Among Men with High-risk Prostate Cancer and Negative Conventional Imaging. <i>European Urology Oncology</i> , 2022, 5, 100-103.	5.4	18
2	Prostate Cancer Disparities in Risk Group at Presentation and Access to Treatment for Asian Americans, Native Hawaiians, and Pacific Islanders: A Study With Disaggregated Ethnic Groups. <i>JCO Oncology Practice</i> , 2022, 18, e204-e218.	2.9	18
3	Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. <i>European Urology</i> , 2022, 81, 466-473.	1.9	12
4	Body fat composition as biomarker for clinical outcomes and treatment tolerance in high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 159-159.	1.6	0
5	Psychological Distress and Access to Mental Health Services Among Cancer Survivors: a National Health Interview Survey Analysis. <i>Journal of General Internal Medicine</i> , 2021, 36, 3243-3245.	2.6	6
6	Mental Distress and Mental Health Services Receipt in Foreign-Born Survivors of Cancer: a National Health Interview Survey Analysis. <i>Journal of General Internal Medicine</i> , 2021, 36, 2495-2498.	2.6	1
7	Surface applicator high-dose-rate fractionated brachytherapy for superficial cancers of the penis: A single-center case series and national database comparison. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 168-172.	1.2	2
8	Head and Neck Cancer Clinical Research on ClinicalTrials.gov: An Opportunity for Radiation Oncologists. <i>Advances in Radiation Oncology</i> , 2021, 6, 100608.	1.2	2
9	Association Between Travel Distance and Use of Postoperative Radiation Therapy Among Men With Organ-Confined Prostate Cancer: Does Geography Influence Treatment Decisions?. <i>Practical Radiation Oncology</i> , 2021, 11, e426-e433.	2.1	3
10	Utilization of multimodality therapy with primary radical prostatectomy versus radiation therapy for Gleason 8-10 prostate cancer. <i>Brachytherapy</i> , 2021, 20, 1-9.	0.5	0
11	Disparities in Mortality from Larynx Cancer: Implications for Reducing Racial Differences. <i>Laryngoscope</i> , 2021, 131, E1147-E1155.	2.0	8
12	Disparities in Refusal of Locoregional Treatment for Prostate Adenocarcinoma. <i>JCO Oncology Practice</i> , 2021, 17, e1489-e1501.	2.9	13
13	Association between percentage of positive biopsy cores and risk of pelvic lymph node involvement in prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 205-205.	1.6	0
14	Factors influencing noncompletion of radiotherapy among men with localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 199-199.	1.6	0
15	Association between travel distance and use of postoperative radiation therapy among men with organ-confined prostate cancer: Does geography influence treatment decisions?. <i>Journal of Clinical Oncology</i> , 2021, 39, 24-24.	1.6	1
16	Radiation Delay Is Okay, but Where Is the Evidence?â€”Reply. <i>JAMA Oncology</i> , 2021, 7, 464.	7.1	0
17	Financial worry and psychological distress among cancer survivors in the United States, 2013-2018. <i>Supportive Care in Cancer</i> , 2021, 29, 5523-5535.	2.2	25
18	Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial. <i>Cancer</i> , 2021, 127, 2213-2221.	4.1	9

#	ARTICLE	IF	CITATIONS
19	Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 1279-1285.	0.8	18
20	US Primary Care vs Specialty Care Trainee Positions and Physician Incomes: Trends From 2001 to 2019. <i>Journal of Graduate Medical Education</i> , 2021, 13, 385-389.	1.3	3
21	Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques. <i>Radiotherapy and Oncology</i> , 2021, 161, 241-250.	0.6	7
22	Clinical characterization of radiation-associated muscle-invasive bladder cancer. <i>Urology</i> , 2021, 154, 208-214.	1.0	3
23	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). <i>Cancer Genetics</i> , 2021, 258-259, 61-68.	0.4	2
24	United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 179-183.	3.9	12
25	Genomic and clinical characterization of stromal infiltration markers in prostate cancer. <i>Cancer</i> , 2020, 126, 1407-1412.	4.1	8
26	Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. <i>Cancer</i> , 2020, 126, 717-724.	4.1	64
27	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020, 38, 735.e9-735.e15.	1.6	2
28	Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities. <i>Prostate</i> , 2020, 80, 1128-1133.	2.3	15
29	Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2020, 6, 1630.	7.1	25
30	Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020, 19, 246-254.e5.	1.9	9
31	Local management of preinvasive and clinical T1-3 penile cancer: utilization of diverse treatment modalities. <i>Future Oncology</i> , 2020, 16, 955-960.	2.4	5
32	Multilingual Analysis of the Quality and Readability of Online Health Information on the Adverse Effects of Breast Cancer Treatments. <i>JAMA Surgery</i> , 2020, 155, 781.	4.3	20
33	Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 936-940.	0.8	3
34	Validation of a subclassification for high-risk prostate cancer in a prospective cohort. <i>Cancer</i> , 2020, 126, 2132-2138.	4.1	7
35	Surgical management versus combination radiotherapy in Gleason score 9-10 prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 135-135.	1.6	1
36	Doublecortin expression in prostate adenocarcinoma and neuroendocrine tumors.. <i>Journal of Clinical Oncology</i> , 2020, 38, 161-161.	1.6	0

#	ARTICLE	IF	CITATIONS
37	Characteristics of radiation-associated bladder cancer compared to primary bladder cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 582-582.	1.6	2
38	Clinical-genomic sub-classification of high-risk prostate cancer: Implications for tailoring therapy and clinical trial design.. <i>Journal of Clinical Oncology</i> , 2020, 38, 337-337.	1.6	0
39	Mental distress and mental health services receipt in foreign-born survivors of cancer: A national health interview survey analysis.. <i>Journal of Clinical Oncology</i> , 2020, 38, e19001-e19001.	1.6	1
40	Prostate-directed radiation therapy and overall survival for men with M1a prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 101-101.	1.6	1
41	Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. <i>Cancer</i> , 2019, 125, 3338-3346.	4.1	15
42	Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 621-627.	0.8	10
43	Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer. <i>Cancer</i> , 2019, 125, 3164-3171.	4.1	35
44	Active Surveillance for Low-Risk Prostate Cancer in Black Patients. <i>New England Journal of Medicine</i> , 2019, 380, 2070-2072.	27.0	42
45	Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy. <i>Brachytherapy</i> , 2019, 18, 198-203.	0.5	1
46	A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. <i>Brachytherapy</i> , 2019, 18, 186-191.	0.5	18
47	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. <i>European Urology</i> , 2019, 75, 35-41.	1.9	18
48	Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 973-978.	0.4	24
49	Active surveillance and watchful waiting for low-risk prostate cancer in black patients: A population-based analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 10-10.	1.6	0
50	Practice Patterns and Outcomes Among Patients With NOMO Prostate Cancer and a Very High Prostate-Specific Antigen Level. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 941-948.	4.9	0
51	Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 157.e15-157.e20.	1.6	6
52	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. <i>American Journal of Medicine</i> , 2018, 131, 517-523.	1.5	13
53	Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 953-959.	1.3	14
54	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, 78-78.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Laboratory eligibility criteria as potential barriers to participation by black men in prostate cancer clinical trials.. Journal of Clinical Oncology, 2018, 36, 73-73.	1.6	1
56	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. Clinical Genitourinary Cancer, 2017, 15, 563-569.e3.	1.9	7
57	Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 542.e25-542.e32.	1.6	6
58	Characterization of efficacy and toxicity after high-dose pelvic reirradiation with palliative intent for genitourinary second malignant neoplasms or local recurrences after full-dose radiation therapy in the pelvis: A high-volume cancer center experience. Advances in Radiation Oncology, 2017, 2, 140-147.	1.2	7
59	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 98, 338-343.	0.8	9
60	Characteristics and national trends of patients receiving treatment of the primary tumor for metastatic prostate cancer. Prostate International, 2017, 5, 89-94.	2.3	3
61	Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer. International Journal of Radiation Oncology Biology Physics, 2017, 99, 904-911.	0.8	6
62	Maximizing resources in the local treatment of prostate cancer: A summary of cost-effectiveness studies. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 76-85.	1.6	21
63	National predictors and trends for androgen deprivation therapy use in low-risk prostate cancer.. Journal of Clinical Oncology, 2017, 35, 50-50.	1.6	0
64	Trends and clinico-sociodemographic determinants of stereotactic body radiotherapy use for localized prostate cancer: A National Cancer Database study.. Journal of Clinical Oncology, 2017, 35, e545-e545.	1.6	0
65	The association of androgen deprivation therapy and anxiety among 78,000 patients with localized prostate cancer patients.. Journal of Clinical Oncology, 2017, 35, 19-19.	1.6	1
66	Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.. Journal of Clinical Oncology, 2017, 35, 18-18.	1.6	0
67	Brachytherapy boost and cancer-specific mortality in favorable high-risk versus other high-risk prostate cancer. Journal of Contemporary Brachytherapy, 2016, 1, 1-6.	0.9	23
68	Association Between Very Small Tumor Size and Increased Cancer-Specific Mortality in Node-Positive Colon Cancer. Diseases of the Colon and Rectum, 2016, 59, 187-193.	1.3	25
69	Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. BJU International, 2016, 118, 279-285.	2.5	14
70	Merkel Cell Carcinoma: A Population Analysis on Survival. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1247-1257.	4.9	57
71	Association Between Travel Distance and Choice of Treatment for Prostate Cancer: Does Geography Reduce Patient Choice?. International Journal of Radiation Oncology Biology Physics, 2016, 96, 313-317.	0.8	51
72	Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 1905-1912.	1.6	121

#	ARTICLE	IF	CITATIONS
73	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. <i>Brachytherapy</i> , 2016, 15, 695-700.	0.5	13
74	National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. <i>Cancer</i> , 2016, 122, 3371-3377.	4.1	27
75	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 421-428.	4.9	10
76	Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 683-690.	0.8	57
77	Recent relocation and decreased survival following a cancer diagnosis. <i>Preventive Medicine</i> , 2016, 89, 245-250.	3.4	7
78	National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. <i>Cancer</i> , 2016, 122, 1505-1512.	4.1	27
79	Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e299-e305.	1.9	11
80	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016, 34, 57.e15-57.e22.	1.6	17
81	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with $\geq 50\%$ Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. <i>Urology</i> , 2016, 87, 125-132.	1.0	16
82	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. <i>BJU International</i> , 2016, 118, 95-101.	2.5	45
83	Risk of prostate cancer mortality in men with a history of prior cancer. <i>BJU International</i> , 2016, 117, E20-8.	2.5	22
84	Re-irradiation of the pelvis for a genitourinary second malignant neoplasm or a local recurrence after full-dose pelvic radiotherapy for a pelvic cancer: Experience in a high-volume cancer center.. <i>Journal of Clinical Oncology</i> , 2016, 34, 494-494.	1.6	0
85	Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 54-54.	1.6	0
86	Socioeconomic disparities in the receipt of radiation for node-positive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 53-53.	1.6	0
87	Brachytherapy boost and cancer-specific mortality in favorable high-risk and other high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 52-52.	1.6	0
88	Duration of androgen deprivation therapy for high-risk prostate cancer: Application of randomized trial data in a tertiary referral cancer center.. <i>Journal of Clinical Oncology</i> , 2016, 34, 33-33.	1.6	0
89	Conditional cancer-specific mortality in T4, N1, or M1 prostate cancer: implications for long-term prognosis. <i>Radiation Oncology</i> , 2015, 10, 155.	2.7	20
90	Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. <i>Brachytherapy</i> , 2015, 14, 511-516.	0.5	4

#	ARTICLE	IF	CITATIONS
91	Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 330.e19-330.e25.	1.6	13
92	Association Between Older Age and Increasing Gleason Score. Clinical Genitourinary Cancer, 2015, 13, 525-530.e3.	1.9	23
93	Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. Journal of Urology, 2015, 194, 343-349.	0.4	109
94	Transfusion in Head and Neck Free Flap Patients. Otolaryngology - Head and Neck Surgery, 2015, 152, 449-457.	1.9	45
95	Dysregulated metabolism contributes to oncogenesis. Seminars in Cancer Biology, 2015, 35, S129-S150.	9.6	225
96	Definition and Validation of "Favorable High-Risk Prostate Cancer" Implications for Personalizing Treatment of Radiation-Managed Patients. International Journal of Radiation Oncology Biology Physics, 2015, 93, 828-835.	0.8	40
97	Designing a broad-spectrum integrative approach for cancer prevention and treatment. Seminars in Cancer Biology, 2015, 35, S276-S304.	9.6	220
98	Pyruvate Kinase Isoform Expression Alters Nucleotide Synthesis to Impact Cell Proliferation. Molecular Cell, 2015, 57, 95-107.	9.7	209
99	Incidence and predictors of upgrading and upstaging among 10,000 contemporary patients with low-risk prostate cancer.. Journal of Clinical Oncology, 2015, 33, 32-32.	1.6	0
100	Incidence and predictors of prostate cancer death in men with other prior malignancies: An analysis from SEER Database.. Journal of Clinical Oncology, 2015, 33, 34-34.	1.6	0